TGTX250502P39500
- 0.95
- 0.000.00%
TG Therapeutics Newsroom
Earnings Preview: TGTX to Report Financial Results on May 05
TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update
TG Therapeutics (NasdaqCM:TGTX) Sees Profitable Turn With Strong Quarterly Earnings
TG Therapeutics Insiders Sold US$2.5m Of Shares Suggesting Hesitancy
TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
SA Analyst Downgrades: TSLA, NFLX, VZ, CSCO, AVGO, TSM, CRWD, RTX
BofA Securities Maintains TG Therapeutics(TGTX.US) With Sell Rating, Maintains Target Price $11
Price Over Earnings Overview: TG Therapeutics
Should TG Therapeutics, Inc. (NASDAQ:TGTX) Focus On Improving This Fundamental Metric?
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $55
Buy Rating for TG Therapeutics Driven by Promising Briumvi Data and Strong Revenue Projections
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals
TG Therapeutics Price Target Raised to $11 From $10 at BofA
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX)
TG Therapeutics Rises After Trial Setback for High Dose Version of Roche's MS Drug
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%?
These 4 Measures Indicate That TG Therapeutics (NASDAQ:TGTX) Is Using Debt Reasonably Well
Eurozone Stock Gains Are Priced in – Time to Return to US's Reign
Wells Fargo Sees Opportunities in MidCaps – Here Are SA's Top Quant-rated